Western University

Scholarship@Western
Physiology and Pharmacology Publications

Physiology and Pharmacology Department

6-1-2019

Poly(ester amide) particles for controlled delivery of celecoxib
Ian J. Villamagna
The University of Western Ontario

Trent N. Gordon
The University of Western Ontario

Mark B. Hurtig
Ontario Veterinary College

Frank Beier
The University of Western Ontario

Elizabeth R. Gillies
The University of Western Ontario

Follow this and additional works at: https://ir.lib.uwo.ca/physpharmpub
Part of the Medical Physiology Commons, and the Pharmacy and Pharmaceutical Sciences Commons

Citation of this paper:
Villamagna, IJ, Gordon, TN, Hurtig, MB, Beier, F, Gillies, ER. 2019. Poly(ester amide) particles for controlled
delivery of celecoxib. J Biomed Mater Res Part A 2019: 107A: 1235– 1243.

SCIENCE TRANSLATIONAL MEDICINE | RESEARCH ARTICLE
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INTRODUCTION

Osteoarthritis (OA) is the most common chronic condition of the
joints, affecting 303 million people globally in 2017 (1). As a joint
degenerative disease, it is primarily characterized by destruction of
articular cartilage but is often accompanied by subchondral bone
thickening, osteophyte formation, synovial inflammation, and hypertrophy of the joint capsule (2). Posttraumatic OA develops after
joint injury and causes an acute form of cartilage degeneration. Patients with OA experience pain and disability, for which there are
neither cures nor disease-modifying treatments.
The outermost superficial layer of articular cartilage is the first
line of defense against OA initiation. Distinct from other layers of
articular cartilage (transitional, middle, and calcified zones), this twoto four-cell-thick superficial zone has distinct biologic and mechanical functions, such as producing lubricant proteins, harboring
chondroprogenitors, resisting shear stresses, and serving as a gliding
surface (3). In OA, degenerative changes are initiated with cellular
disorganization and irregular surface of the superficial layer (4–6).
The epidermal growth factor receptor (EGFR) is one of the most
well-studied signaling pathways. Upon activation by its ligands,
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EGFR dimerizes with itself or other members of the EGFR family to
modulate a variety of cellular functions, such as proliferation, survival, adhesion, migration, and differentiation (7). Mice lacking
EGFR activity specifically in cartilage (Col2-Cre) have fewer superficial chondrocytes, less secretion of boundary lubrication, and
weak mechanical strength at the cartilage surface than their wildtype (WT) siblings (8). With a defective articular cartilage surface,
these mice develop markedly accelerated knee OA during aging or
after OA injury (8, 9). Mig6 is a negative feedback inhibitor of EGFR
(10). Consistently, mice with Mig6 deficiency in cartilage or limb
bud mesenchyme display thickened articular cartilage with a drastically increased number of superficial chondrocytes at a young age
(11–13). Together, these lines of evidence suggest that the EGFR
pathway is critical for maintaining homeostasis of the superficial
layer of articular cartilage.
We hypothesized that targeting the EGFR pathway could be an
effective OA therapy. To test this, we designed a two-pronged
approach. First, we genetically enhanced EGFR activity by adopting
a Rosa-diphtheria toxin receptor (DTR) model that is normally used
for cell ablation (14). Originally identified as a receptor for bacterial
diphtheria toxin, DTR was later found to be human full-length heparin binding EGF-like growth factor (HBEGF) (15), a ligand for
EGFR. Human HBEGF shares 81% sequence identity with the
mouse ortholog. Breeding Rosa-DTR mice with cartilage-specific
Col2-Cre or Aggrecan-CreER mice allowed us to study the effect of
cartilage-specific EGFR overactivation on OA progression. Second,
we developed an advanced nanoparticle (NP)–based system for the
local delivery of an EGFR ligand, transforming growth factor–
(TGF), into knee cartilage. Because TGF, the most highly expressed EGFR ligand in mouse cartilage (8), has a short life span of
20 min in the circulation (16), it is not feasible to use TGF directly
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Osteoarthritis (OA) is a widespread joint disease for which there are no disease-modifying treatments. Previously,
we found that mice with cartilage-specific epidermal growth factor receptor (EGFR) deficiency developed accelerated
knee OA. To test whether the EGFR pathway can be targeted as a potential OA therapy, we constructed two
cartilage-specific EGFR overactivation models in mice by overexpressing heparin binding EGF-like growth factor
(HBEGF), an EGFR ligand. Compared to wild type, Col2-Cre HBEGF-overexpressing mice had persistently enlarged
articular cartilage from adolescence, due to an expanded pool of chondroprogenitors with elevated proliferation
ability, survival rate, and lubricant production. Adult Col2-Cre HBEGF-overexpressing mice and Aggrecan-CreER
HBEGF-overexpressing mice were resistant to cartilage degeneration and other signs of OA after surgical destabilization of the medial meniscus (DMM). Treating mice with gefitinib, an EGFR inhibitor, abolished the protective
action against OA in HBEGF-overexpressing mice. Polymeric micellar nanoparticles (NPs) conjugated with transforming growth factor– (TGF), a potent EGFR ligand, were stable and nontoxic and had long joint retention,
high cartilage uptake, and penetration capabilities. Intra-articular delivery of TGF-NPs effectively attenuated
surgery-induced OA cartilage degeneration, subchondral bone plate sclerosis, and joint pain. Genetic or pharmacologic activation of EGFR revealed no obvious side effects in knee joints and major vital organs in mice. Together,
our studies demonstrate the feasibility of using nanotechnology to target EGFR signaling for OA treatment.
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as an OA drug. Recently, NP-based targeted drug delivery has been
pursued in the treatment of OA (17–19). A strength of these delivery
systems is the prolonged retention of drugs in the joints, thus lowering the overall therapeutic dose required and reducing off-target
toxicity and side effects. To increase the retention and minimize the
leakage of TGF from the joint space, we synthesized TGF-NPs by
conjugating TGF onto the surfaces of polymeric micellar NPs. We
then characterized the properties of these TGF-NPs in the joint
tissue and performed a proof-of-principle study by testing their
efficacy in attenuating OA progression in a mouse injury model.
RESULTS

Fig. 1. Overexpression of HBEGF in chondrocytes expands mouse growth plate and articular cartilage without affecting the gross appearance of knee joints.
(A) Western blot of HBEGF and EGFR downstream signals (p-EGFR and p-ERK) in articular cartilage chondrocytes derived from 5-month-old HBEGF OverCol2 mice. n = 3
independent experiments. (B) Safranin O/Fast Green staining of knee joints from 5- or 12-month-old HBEGF OverCol2 and control littermates (WT). M, month. Scale bars,
1 mm. n = 3 mice per group. (C) Safranin O/Fast Green staining of tibial growth plate in WT and HBEGF OverCol2 mice at 1 and 5 months of age. Scale bar, 200 m. (D) The
thicknesses (Th.) of the proliferative zone (PZ) and hypertrophic zone (HZ) in the growth plate of 1-month-old mice. n = 5 mice per group. (E) The growth plate thickness
(GP Th.) quantified from 1- and 5-month-old mice. n = 5 mice per group. (F) Safranin O/Fast Green staining of articular cartilage in WT and HBEGF OverCol2 knee joints at
1 and 5 months of age. Scale bar, 200 m. (G) Average thicknesses of the uncalcified zone (Uncal. Th.), calcified zone (Cal. Th.), and total tibial articular cartilage quantified
from 1- and 5-month-old mice. n = 8 mice per group. Statistical analysis was performed using two-way ANOVA with Bonferroni’s post hoc analysis. Data are presented as
means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001.
Wei et al., Sci. Transl. Med. 13, eabb3946 (2021)
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Overexpression of HBEGF in chondrocytes leads to
cartilage enlargement
To target the EGFR pathway in cartilage, we generated Col2-Cre
Rosa-DTR mice [Col2-Cre Rosa-HBEGF (HBEGF OverCol2) mice].

These mice had similar body weight and body length as WT mice
(fig. S1). Western blots (Fig. 1A) and immunohistochemistry (IHC;
fig. S2) confirmed that there was increased HBEGF in chondrocytes, leading to EGFR activation as shown by elevated phospho-
EGFR (p-EGFR) and phospho–extracellular signal–regulated kinase
(p-ERK) amounts (Fig. 1A). HBEGF OverCol2 mice at 5 and 12 months
of age displayed normal knee joints (Fig. 1B) without gross abnormalities, such as osteophytes or synovitis (fig. S3). Long bone structure,
including subchondral trabecular bone, subchondral bone plate (SBP),
and metaphyseal trabecular bone, was also not affected (fig. S4).
The most obvious change in the HBEGF OverCol2 skeleton is cartilage. At 1 month of age, its growth plate was modestly expanded
by 16%, mainly due to the elongation of the proliferative zone
(Fig. 1, C to E). On the contrary, its hypertrophic zone was shrunk.
At 5 months of age, the expansion of growth plate was more obvious (2.41-fold). Similar expansion was also observed in articular
cartilage (23 and 34% increases in total cartilage thickness at 1 and
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5 months of age, respectively) with a major change in uncalcified
cartilage but not in calcified cartilage (Fig. 1, F and G).
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EGFR overactivation expands the chondroprogenitor pool
The superficial layer contains chondroprogenitors responsible for
forming cells in the rest of articular cartilage during development
(20). Our previous study showed that EGFR inactivation in chondrocytes (Col2-Cre CKO) leads to fewer superficial chondrocytes
(8). In WT joints, the number of chondrocytes in the superficial
zone declined by 39% during cartilage maturation (Fig. 2, A and B).
This decline did not occur in HBEGF OverCol2 mice, which exhibited
a 1.79-fold increase in superficial chondrocytes compared to WT at
5 months of age (Fig. 2, A and B). This was accompanied by enhanced Ki67 and proteoglycan 4 (PRG4) staining and reduced terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end
labeling (TUNEL) staining (Fig. 2, C and D) in HBEGF OverCol2 mice,
suggesting that constitutive overactivation of EGFR signaling promotes proliferation, survival, and lubricant synthesis in chondrocytes.
5-Ethynyl-2′-deoxyuridine (EdU) labels cells undergoing proliferation. At 1 week of age, 46% of periarticular cells in epiphyseal
cartilage, the site for future articular cartilage, were labeled in WT
mice (Fig. 2, E and F). Three weeks later when articular cartilage is
established, 27% of chondrocytes (most of them in uncalcified cartilage) were still labeled by EdU, indicating that many proliferative
chondrocytes are slow-cycling cells, i.e., chondroprogenitors. HBEGF
OverCol2 mice had more EdU+ cells than WT mice at 4 weeks of age
(Fig. 2, E and F). After dissection and digestion, 5-month-old
HBEGF OverCol2 cartilage formed 1.96-fold more colony-forming
unit fibroblast (CFU-F) colonies than WT cartilage in culture
(Fig. 2, G and H). In addition, progenitors from HBEGF OverCol2
cartilage grew much quicker than those from WT (Fig. 2I) and were
resistant to tumor necrosis factor– (TNF)–induced apoptosis
(Fig. 2J). Meanwhile, synovial mesenchymal progenitors were not
affected (fig. S5). Together, our in vivo and in vitro data demonstrate that HBEGF overexpression produces more chondroprogenitors in articular cartilage with superior proliferation and survival
abilities.
When subjected to chondrogenic differentiation, progenitors
from HBEGF OverCol2 cartilage expressed more Prg4 but less cartilage matrix (Aggrecan, Col2a1, and Col10a1) and protease (Mmp13)
markers (Fig. 2K). They differentiated into Alcian blue–positive
cartilage, albeit the staining intensity was less than WT (Fig. 2L).
These in vitro data indicate that overexpression of HBEGF modestly
decreases chondrogenic differentiation; however, immunostaining
confirmed that proteoglycan, type II collagen, type X collagen, and
MMP13 (fig. S6) amounts were not altered in HBEGF OverCol2 cartilage, suggesting that overactivation of EGFR signaling does not
negatively affect cartilage components in vivo.
As a transmembrane protein, HBEGF is cleaved by a sheddase
and released from the cell membrane for paracrine and systemic
actions (21). Because EGFR is important for the development and
homeostasis of multiple organs, a concern is raised about possible
side effects of constitutively expressing HBEGF. However, we did
not observe p-EGFR in major organs, such as heart, liver, spleen,
lung, kidney, and brain from adult HBEGF OverCol2 mice (fig. S7A).
Endogenous EGFR and HBEGF were also not altered (fig. S7A).
The morphology of these vital organs remained the same as WT
mice at 5 and 12 months of age (fig. S7B), indicating no substantial
side effects of cartilage-specific HBEGF overexpression.

EGFR overactivation attenuates OA progression
Next, we sought to study the effect of HBEGF overexpression on
OA progression induced by surgical destabilization of the medial
meniscus (DMM) (Fig. 3A). Two months after surgery, WT knees
started to lose proteoglycan and exhibit fibrillation at the cartilage
surface (Fig. 3, B and C). At 4 months after surgery, WT knees displayed severe cartilage erosion beyond the tidemark, accompanied
by uneven cartilage surface or clefts. In contrast, knees in HBEGF
OverCol2 mice showed only a minor loss in proteoglycan content
2 months after DMM surgery. Two months later, the articular surface was still intact, although cartilage was thinner than that in
sham knees. Quantifying OA severity at 4 months after surgery
revealed that overexpression of HBEGF reduced Mankin score
from 10.0 to 2.1 at this stage (Fig. 3C). These data provided in vivo
evidence that overactivation of EGFR could protect cartilage from
degeneration upon OA-inducing insults.
To eliminate the developmental effect in HBEGF Over Col2
mice, we next constructed an inducible model Aggrecan-CreER DTR
(HBEGF OverAgcER). These mice had normal articular cartilage
before injury since tamoxifen was injected immediately before
DMM surgery (Fig. 3D). IHC confirmed higher amounts of
HBEGF and p-EGFR in articular cartilage of HBEGF OverAgcER
compared to the sham knees 1 month after induction (fig. S8).
Four months after DMM surgery, whereas WT mice developed
late OA with most cartilage eroded, HBEGF OverAgcER maintained
relatively intact articular cartilage with a low Mankin score of 2.5
(Fig. 3, E and F). Our prior study demonstrated that nanoindentation of the cartilage surface is a sensitive method to detect early
OA in mice (22). In line with this, the surface indentation modulus
Eind was drastically reduced by 67% in WT cartilage at 1 month
after DMM but remained unchanged in HBEGF OverAgcER mouse
knees (Fig. 3G), suggesting that overexpressing HBEGF in adult
cartilage preserves the mechanical functions of the cartilage surface
after OA injury.
HBEGF binds and signals through EGFR as well as another EGFR
family member, ErbB4 (23). To study whether EGFR mediates the
action of HBEGF on cartilage in vivo, we treated HBEGF OverAgcER
mice and WT controls with the EGFR-specific inhibitor gefitinib
(24) once every other day for 2 months after tamoxifen induction
and DMM surgery. Similar to our previous data (25), gefitinib moderately accelerated OA progression in WT DMM knees, increasing
Mankin score from 6.5 to 9.8 (Fig. 4, A and B). Gefitinib completely
abolished the protective effect of HBEGF OverAgcER on articular cartilage after DMM surgery, leading to marked cartilage erosion with
an elevated Mankin score of 9.0. DMM mainly reduced the thickness of uncalcified cartilage, resulting in 38 and 74% decreases in
vehicle- and gefitinib-treated WT mice, respectively (Fig. 4C). In
HBEGF OverAgcER mice, although DMM alone did not alter the cartilage thickness, cotreatment with gefitinib greatly lessened the
thicknesses of uncalcified and total cartilage by 75 and 59%, respectively (Fig. 4C). Furthermore, the von Frey behavioral pain test
indicated that HBEGF OverAgcER mice developed a similar degree of
pain as WT mice at 1 week after DMM but quickly recovered to
baseline as sham mice, suggesting that overexpressing HBEGF also
has functional benefits (Fig. 4D). However, gefitinib abolished this
effect. We did not detect any effect of this inhibitor on sham knees
from WT or HBEGF OverAgcER mice. Therefore, our results indicated
that HBEGF signals through EGFR in vivo to execute its chondroprotection action.
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Synthesis and characterization of TGF-NPs
Cartilage expresses TGF and other EGFR ligands (8); however, the
above mouse studies indicated that endogenous EGFR ligand exWei et al., Sci. Transl. Med. 13, eabb3946 (2021)
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pression is not sufficient to protect cartilage against OA. To activate
EGFR for OA treatment, we chose one of the most potent EGFR ligands, TGF (26), as an activator. However, TGF is not stable in
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Fig. 2. Overexpression of HBEGF increases chondroprogenitors in articular cartilage. (A) Hematoxylin and eosin staining of femoral articular cartilage from WT and
HBEGF OverCol2 mice at 1 and 5 months of age. Scale bar, 50 m. (B) Chondrocyte numbers (CH) in superficial zone (SZ), transition and middle zones (TZ + MZ), calcified
zone (CZ), and entire femoral articular cartilage quantified at 1 and 5 months of age. n = 8 mice per group. (C) Immunostaining of Ki67, TUNEL, and PRG4 in tibial articular
cartilage of 5-month-old WT and HBEGF OverCol2 mice. Scale bar, 50 m. (D) The percentages of Ki67+, TUNEL+, and Prg4+ cells within articular cartilage were quantified.
n = 8 mice per group. (E) Long-term EdU labeling of slow-cycling cells in the tibial articular cartilage of HBEGF OverCol2 mice. Mice received daily EdU injections from postnatal days 4 to 6, and their joints were harvested at 1 and 4 weeks of age for EdU staining. Dashed lines outline periarticular layer (1 week of age) and articular cartilage
(4 weeks of age) for analysis. Scale bar, 100 m. (F) Quantification of EdU+ cells in outlined regions. n = 5 mice per group. (G) CFU-F assay using chondrocytes dissociated
from mouse knee joints from 5-month-old WT and HBEGF OverCol2 mice. Scale bar, 0.5 cm. (H) Quantification of CFU-F frequency. n = 5 mice per group. (I) Proliferation of
primary chondroprogenitors from 5-month-old WT or HBEGF OverCol2 knee joints. Cells were seeded at the same density on day 0, and their numbers were counted every
other day. n = 5 independent experiments. (J) Apoptosis assay of primary chondrocytes from 5-month-old WT and HBEGF OverCol2 knee joints. Cells were incubated with
or without TNF (25 ng/ml) or vehicle (Veh; PBS) for 2 days before analysis. n = 5 independent experiments. (K) qRT-PCR analyzes the relative gene expression in chondroprogenitors from WT and HBEGF OverCol2 knee joints undergoing 2 weeks of chondrogenic differentiation. n = 3 independent experiments. (L) Alcian blue staining of
chondroprogenitors after 2 weeks of chondrogenic differentiation. Scale bar, 200 m. n = 3 independent experiments. Statistical analysis was performed using two-way
ANOVA with Tukey’s post hoc analysis for (B), (F), and (J) and unpaired t test for (D), (H), (I), and (K). Data are presented as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001.
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to augment the interaction between
the therapeutic agents and the anionic
glycosaminoglycans in the cartilage,
the cationic diblock copolymer PLLPCL was synthesized (fig. S9) and introduced into the PEG-PCL NPs to reduce
their surface charge from −4.2 to −1 mV
(Fig. 5C). After the conjugation of TGF,
the surface charge of TGF-NPs became more negative, mostly due to the
negatively charged TGF. However, the
magnitude of the surface charge of TGF-
NPs was still reduced in NPs containing
PLL-PCL. For example, the surface charges
of TGF-NPs in the presence and absence of PLL-PCL were −13.7 and −19.4 mV,
respectively. We next characterized stability, cytotoxicity, and specificity of
newly synthesized TGF-NPs. We did
not detect any change in the hydrodynamic diameter of TGF-NPs in water
for at least 1 week (Fig. 5D) or in bovine
synovial fluid for 24 hours (Fig. 5E).
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay
showed that TGF-NP treatment (up to
10 M TGF content) for 24 hours did
not affect the viability of mouse primary
chondrocytes (Fig. 5F). Western blot
demonstrated that TGF-NPs activated
Fig. 3. Overexpressing HBEGF in articular cartilage delays OA progression. (A) Schematic showing the study
EGFR downstream target ERK as poprotocol of WT and HBEGF OverCol2 mice with DMM surgery at 3 months of age. H indicates time points when histology
tently as free TGF, whereas Ctrl-NPs
was performed. (B) Safranin O/Fast Green staining of DMM and sham joints at the medial site from 5- and 7-month-old
WT and HBEGF OverCol2 mice. Low: low-magnification image; high: high-magnification image of the yellow boxed
(NP with no TGF conjugation) had no
area above. Scale bars, 200 m. (C) The OA severity was measured by Mankin score. n = 8 mice per group. (D) Schesuch effect (Fig. 5, G and H). In addimatic showing the study protocol of WT and HBEGF OverAgcER mice with tamoxifen (Tam) injections and DMM surgery
tion, similar to free TGF, TGF-NPs
at 3 months of age. (E) Safranin O/Fast Green staining of WT and HBEGF OverAgcER DMM and sham joints at the medial
changed chondrocytes from a polygonal
site from mice 7 months of age. Scale bars, 200 m. (F) The OA severity was measured by Mankin score. n = 8 mice per
cell shape to a more spindle cell shape
group. (G) Nanoindentation assay was performed on the femoral cartilage surface at 1 month after surgery. Eind,
after 2 days of treatment (fig. S10). Using
modulus. n = 4 to 5 mice per group. Statistical analysis was performed using two-way ANOVA with Tukey’s post hoc
fluorescent rhodamine-labeled TGF-NPs,
analysis. Data are presented as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001.
we found that TGF-NPs bound to the
surface of primary chondrocytes in a
TGF-specific manner (Fig. 5I). Morethe circulation, and direct injection of it into knee joints suffers over, in human articular cartilage explants, TGF-NPs activated
from rapid clearance due to its low molecular weight (5.6 kDa). To ERK (fig. S11A); reduced the expression of chondrocyte markers
overcome this challenge, we engineered an NP delivery system to Sox9, Aggrecan, and Col2a1; and elevated the expression of lubriprolong the retention of active TGF in the knee joint. Briefly, cant Prg4, cyclin gene Ccnd1, and proteinase MMP13 (fig. S11B).
bacteria-expressed human TGF were synthesized and site-specifically These results are consistent with previous studies reporting the
labeled at the C terminus with a constrained alkyne, dibenzocy- effect of TGF on rodent and bovine cartilage explants (29).
clooctyne (DBCO), via sortase-tag–expressed protein ligation (27, 28). TGF-NPs decreased the expression of Adamts5, the major aggrecaTGF-NPs were then prepared via copper-free click chemistry, nase, in human cartilage, which is also in line with a previous report
by simply mixing TGF-DBCO with azide-functionalized NPs studying TGF actions on rat chondrocytes (30). Together, our data
(Fig. 5A). Azide-functionalized NPs were made from 55 mole demonstrate that TGF-NPs are stable, nontoxic, and functional.
percent (mol %) poly(ethylene glycol)-polycaprolactone (PEG-PCL)/
20 mol % poly[l-lysine-block-poly(-caprolactone)] (PLL-PCL)/ TGF-NP cartilage uptake, penetration, and joint retention
25 mol % 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- Human knee articular cartilage is about 2 to 4 mm thick, and the
[azido(polyethylene glycol)-5000] (DSPE-PEG5K-N3) using the film superficial layer makes up 10 to 20% of cartilage thickness (31). To
hydration method.
increase cartilage retention and to penetrate deeper into the cartilage,
TGF-NPs resembled spheres with a hydrodynamic diameter we doped cationic PLL-PCL into the NPs to reduce their surface
of 25.93 nm (Fig. 5B). Because NP surface charge could be adjusted charge. Using a near-infrared fluorescence probe IRDye 800CW as
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a label, we found that bovine cartilage explants took up much more
PLL-PCL–doped TGF-NPs than non–PLL-PCL–doped TGF-NPs
or TGF-DBCO after a 24-hour incubation (fig. S12). To study
penetration, we labeled TGF-NPs and TGF-DBCO with rhodamine.
TGF-DBCO and non–PLL-PCL–doped TGF-NPs only accumulated at the cartilage surface but did not penetrate deep inside the
cartilage over a 6-day culture period (Fig. 6, A and B, and fig. S13, A
to D). PLL-PCL–doped TGF-NPs efficiently bound to the surface
of bovine cartilage explants at day 2 and gradually penetrated inside
by at least 1 mm by day 6 (Fig. 6, A and B, and fig. S13, E and F).
Quantitative analysis of the fluorescence images revealed that PLLPCL–doped TGF-NPs exhibited more than a 4.76-fold improvement
in cartilage penetration at day 6 compared with non–PLL-PCL–
doped TGF-NPs (Fig. 6C) with an estimated diffusivity of 1.1 m2/s.
This result demonstrated the improved cartilage penetration and
accumulation of TGF-NPs with PLL-PCL.
Next, we directly injected TGF-NPs or TGF-DBCO labeled
with IRDye 800CW into the knee joint to study retention under
healthy and OA conditions (Fig. 6D). DMM was performed on the
joints 2 months before injection to mimic OA. After a single injection, the fluorescence signal in joints injected with TGF-NPs was much
higher than those injected with TGF-DBCO at all time points,
indicating the increased retention of TGF-NPs (Fig. 6E). Quantitative
Wei et al., Sci. Transl. Med. 13, eabb3946 (2021)

13 January 2021

analysis of fluorescence images showed that TGF-NPs in OA joints
were retained even longer than those in healthy joints (Fig. 6F).
We also examined the biodistribution of TGF-NPs in internal
organs, blood, and joint components. At 24 hours after injection,
fluorescent signals were detected on the cartilage surfaces of the patella, femoral condyles, and the tibial plateau, as well as on meniscus
(fig. S14, A and B). TGF-NPs were mainly accumulated in liver
and kidneys, but no signal was detected in the blood, heart, and
spleen, indicating that NPs can be cleared quickly from circulation.
One month later, there were no TGF-NPs left in liver and kidney
(fig. S14, C and D).
TGF-NP rescue of OA cartilage degeneration after
DMM surgery
To test their therapeutic effect on OA, we injected TGF-NPs into
mouse knee joints after DMM once every 3 weeks. Control groups
include knee joints injected with phosphate-buffered saline (PBS),
TGF-DBCO, and Ctrl-NPs (NP with no TGF conjugation). In
line with our previous findings (8), EGFR activity, as indicated by
p-EGFR, was decreased in PBS-treated articular cartilage after
DMM (Fig. 7A). Injections of TGF-NPs, but not TGF-DBCO or
Ctrl-NPs, successfully elevated cartilage EGFR activity to that of the
sham group (Fig. 7A). At 2 and 3 months after surgery, both the
6 of 14
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Fig. 4. The protective action of HBEGF overexpression on articular cartilage during OA development is EGFR dependent. (A) Safranin O/Fast Green staining of
vehicle- and gefinitib (Gef)–treated WT and HBEGF OverAgcER knee joints at the medial site 2 months after surgery. Low: low-magnification image; high: high-magnification
image of the yellow boxed area above. Scale bars, 200 m. (B) The OA severity was measured by Mankin score. n = 8 mice per group. (C) Average thicknesses of uncalcified
(Uncal. Th.) and total (Total Th.) cartilage quantified at 2 months after surgery. n = 8 mice per group. (D) von Frey assay was performed at 0, 1, 2, 4, and 8 weeks after surgery. PWT, paw withdrawal threshold. n = 8 mice per group. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc analysis for (D) and two-way
ANOVA with Tukey’s post hoc analysis for (B) and (C). Data are presented as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 in (B) and (C). *P < 0.05 and ***P < 0.001 for
DMM WT versus sham WT; $$$P < 0.001 for DMM HBEGF OverAgcER versus DMM WT; &&&P < 0.001 for DMM HBEGF OverAgcER versus DMM HBEGF OverAgcER Gef in (D).
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TGF-DBCO group and Ctrl-NP group displayed a similar pattern
of cartilage degeneration, including erosion and surface fibrillation,
similar to the PBS group (Fig. 7B). Mankin scores of these three
control groups at 3 months after DMM were similarly around
8.5 (Fig. 7C), mainly due to the reduction of uncalcified cartilage
thickness (Fig. 7D). Knee joints in the TGF-NP group maintained
cartilage integrity at 2 months after DMM and displayed minor
signs of degeneration at 3 months after DMM (Fig. 7B). The Mankin
scores at both 2 and 3 months were markedly decreased compared
to control groups and their uncalcified zones were largely preserved
(Fig. 7, C and D, and fig. S15). Similar results were also observed
when TGF-NP injections started 1 month after DMM (to allow
early OA develop) (fig. S16).
Wei et al., Sci. Transl. Med. 13, eabb3946 (2021)
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To understand the mechanism underlying the therapeutic effect
of EGFR overactivation, we performed IHC of EGFR downstream
targets in sham and DMM knees at 2 months after surgery of
HBEGF OverCol2 mice and TGF-NP–injected WT mice (fig. S17).
Consistent with the cartilage degeneration phenotype, DMM reduced the amounts of anabolic factors, such as p-ERK and PRG4,
and increased the amounts of catabolic factors, such as MMP13 and
ADAMTS5, in the articular cartilage. Overexpression of HBEGF or
intra-articular injection of TGF-NP efficiently reversed those
changes, resulting in similar staining patterns of those proteins
between sham and DMM knees of these mice.
Subchondral bone sclerosis is a late OA symptom. Our previous study
established a three-dimensional micro–computed tomography (3D
7 of 14
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Fig. 5. Preparation and characterization of TGF-NPs. (A) Schematic diagram of TGF-NPs. TGF-NPs were prepared by conjugating TGF onto polymeric micellar NPs
via copper-free click chemistry. (B) Dynamic light scattering (DLS) measurements of TGF-NP hydrodynamic diameter (size) and representative image of TGF-NPs examined by transmission electron microscopy. Scale bar, 100 nm. (C) Zeta potential measurements of TGF-DBCO, PEG-PCL NPs with or without PLL-PCL, and TGF-NPs with
or without PLL-PCL in 0.1× PBS (pH 7.4). PLL+ denotes the NPs that contain PLL-PCL, and PLL− denotes the NPs that do not contain PLL-PCL. n = 3 independent experiments. (D) Stability of TGF-NPs in water was evaluated by monitoring DLS measurement of TGF-NP hydrodynamic diameter for up to 7 days. n = 3 independent experiments. (E) Stability of TGF-NPs in bovine synovial fluid of knee joint was evaluated by monitoring DLS measurement of TGF-NP hydrodynamic diameter for up to
24 hours. n = 3 independent experiments. (F) Cell viability of primary mouse chondrocytes after incubation with TGF-NPs at different concentrations. n = 3 independent
experiments. (G) Western blot of EGFR downstream signal (p-ERK) in articular cartilage chondrocytes treated by vehicle (PBS), free TGF (15 ng/ml), Ctrl-NPs (i.e., no TGF
conjugation), or TGF-NPs (15 or 100 ng/ml of TGF content). (H) Quantitative analysis of the relative protein amount (p-ERK/ERK) based on the images of Western blot
as in (G). n = 3 independent experiments. (I) Confocal images of mouse primary chondrocytes treated with vehicle (PBS), TGF-NPs (10 nM TGF content), or TGF-NPs (10
nM TGF content) in the presence of free TGF (100 g/ml). Scale bar, 50 m. n = 3 independent experiments. Statistical analysis was performed using one-way ANOVA
with Dunnett’s post hoc analysis. Data are presented as means ± SEM. **P < 0.01 and ***P < 0.001.
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DISCUSSION

Previous studies from our group and
others have demonstrated the impor
tant role of EGFR signaling in the development of articular cartilage and in OA
progression (29). EGFR signaling can
execute both anabolic and catabolic
actions on cartilage chondrocytes; however, differences exist regarding how
this signaling pathway may be best modulated for OA treatment. In the present
study, we first provide genetic evidence
demonstrating that overactivation of
Fig. 6. TGF-NPs exhibit full-length penetration of human-thickness bovine articular cartilage and extend
EGFR signaling modestly thickens the
residence time in both healthy and diseased knee joints. (A) Representative confocal microscopy images of a
articular cartilage and completely blocks
cross section of bovine cartilage explants incubated with rhodamine-labeled TGF-NPs with or without PLL-PCL or
OA progression after DMM surgery.
free TGF for 2, 4, and 6 days. Arrow indicates the diffusion direction. Scale bar, 200 m. (B) Quantitative analysis of
Other joint tissues, such as bone, syTGF-NP penetration depth into bovine cartilage explants after 6-day incubation. n = 3 per group. (C) Quantitative
novium, and meniscus, appeared noranalysis of area under the curve (AUC) based on fluorescence intensity profiles in (B). n = 3 per group. (D) Represent
mal in mice up to 12 months of age and
ative fluorescence images of healthy and OA mouse knee joints over 28 days after intra-articular injection of IRDye
showed no pathological OA changes,
800CW–labeled TGF or TGF-NPs. (E) Quantitative analysis of time course fluorescence radiant efficiency within
such as osteophytosis and subchondral
knee joints after intra-articular injection of IRDye 800CW–labeled TGF or TGF-NPs. n = 6 per group. (F) Quantitative
bone sclerosis, suggesting that EGFR siganalysis of area under the curve based on fluorescence intensity profile in (E). n = 6 per group. Statistical analysis was
naling could be precisely applied in vivo
performed using one-way ANOVA with Tukey’s post hoc analysis. Data are presented as means ± SEM. ***P < 0.001.
AU, arbitrary units.
to fulfill its anabolic actions without inciting catabolic effects. We then provided
microCT) approach to accurately measure the thickness of SBP (9). proof-of-principle evidence that administration of TGF into mouse
Using this method, we confirmed that SBP thicknesses were elevated joints using an advanced NP delivery system is effective in attenuatin PBS-treated, TGF-DBCO–treated, and Ctrl-NP–treated DMM ing DMM-induced OA initiation and development.
knees relative to sham (Fig. 7, E and F). However, this increase was
One mechanism underlying the therapeutic action of EGFR sigabolished in TGF-NP–treated DMM knees. Synovitis is another sign naling is that EGFR activation promotes the lubrication function of
of OA (32). We observed thickening of the synovial lining layer and articular cartilage, particularly the expression of lubricant Prg4. In
increased synovitis scores in DMM knees with PBS, TGF-DBCO, humans, loss-of-function PRG4 mutation results in camptodactyly–
or Ctrl-NP treatment but not with TGF-NP treatment relative arthropathy–coxa vara–pericarditis syndrome with precocious joint
to sham (Fig. 7, G and H). Moreover, von Frey assay revealed that failure (33). Mice lacking Prg4 display early OA (34). On the conTGF-NP treatment attenuated OA-induced pain starting from trary, intra-articular treatment with recombinant PRG4 prevented
Wei et al., Sci. Transl. Med. 13, eabb3946 (2021)
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2 weeks after surgery (Fig. 7I). Together,
these results demonstrate a therapeutic
effect of intra-articular delivery of EGFR
ligand–conjugated polymeric micellar NP.
Last, we examined whether 2 months
of intra-articular injections of TGF-NPs
caused any side effects to several major
internal organs or to overall joint structure in WT mice. As shown in fig. S18A,
we did not detect any obvious morphologic changes in heart, liver, spleen, lung,
kidney, and brain between PBS-treated
and TGF-NP–treated mice. Western
blots indicated no change in EGFR
activity in those organs after TGF-NP
injections (fig. S18B). Liver and lung
had the highest expression of EGFR
and TGF, which were not affected by
TGF-NP injections. Furthermore, the
gross morphology of knee joints was
not altered by 2 months of TGF-NP
treatment (fig. S18C).
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cartilage (8). In the current study, we
found that EGFR overactivation, either
by overexpressing HBEGF or administration of TGF-NPs, preserved PRG4
in articular cartilage, which is otherwise
diminished in OA. Together, we believe
that PRG4 plays a critical role in mediating the chondroprotective action of
EGFR signaling.
Currently, there are no disease-modifying
drugs clinically approved for treating OA.
Nonsteroidal anti-inflammatory agents
have often been used for the short-term
management of the pain symptoms in
OA. More recently, several protein therapies, such as insulin-like growth factor
(IGF) (37) and fibroblast growth factor
18 (38), have shown promise for OA
treatment. However, intra-articular delivery of these therapeutic proteins has
been largely limited by their rapid clearance from the joint space and their low
penetration into the dense, avascular
cartilage matrix. Consistent with this, we
also observed that intra-articular injection of free TGF had low joint retention and poor cartilage penetration and
thus was ineffective in preventing OA
development and progression. Because
of its favorable pharmacokinetics, biodistribution, and specificity, NP-based
drug delivery systems have been explored to improve drug delivery and
therapeutic efficacy in OA treatment.
For example, Geiger et al. (17) developed dendrimer-based nanocarriers to
deliver IGF-1 to chondrocytes within
Fig. 7. TGF-NP treatment attenuates OA progression after DMM surgery in mice. (A) Immunostaining of p-EGFR
joint cartilage. The dendrimer IGF-1
in mouse knee cartilage at 1 month after sham or DMM surgery. In the DMM group, mice were divided into four
could penetrate full-thickness bovine cargroups receiving PBS, TGF-DBCO, Ctrl-NP, or TGF-NP intra-articular treatments. Scale bar, 100 m. n = 3 mice per
tilage and enhance the efficacy of IGF-1
group. (B) Safranin O/Fast Green staining of knee joints at the medial site at 2 and 3 months after surgery. Low:
in protecting both cartilage and bone in
low-magnification image; high: high-magnification image of the yellow boxed area above. Scale bars, 200 m. (C) The
a rat surgical model of OA. Yan et al.
OA severity of knee joints at 3 months after surgery measured by Mankin score. n = 8 mice per group. (D) Average
(19) used NP-based small interfering
uncalcified (Uncal. Th.) cartilage thickness of knee joints at 3 months after surgery was quantified. n = 8 mice
RNA delivery to attenuate early inflamper group. (E) Representative 3D color maps derived from microCT images showing SBP thickness (SBP Th.). Color
mation in OA development.
ranges from 0 (blue) to 320 m (red). (F) SBP thickness at the medial posterior site of femoral condyle was calculated.
n = 8 mice per group. (G) Hematoxylin and eosin staining of mouse knee joints focusing on synovium at 2 months
We have addressed the TGF delivery
after surgery. Red boxed areas indicate the synovial tissues. Scale bar, 200 m. (H) Synovitis score was measured. n = 8
challenges by conjugating TGF onto
mice per group. (I) von Frey assay was performed at 0, 1, 2, 4, 8, and 12 weeks after surgery. n = 8 per group. Statistical
nanometer-sized polymeric micellar NPs.
analysis was performed using one-way ANOVA with Tukey’s post hoc analysis. Data are presented as means ± SEM.
Polymeric micellar NPs are nanoscopic
*P < 0.05, **P < 0.01, and ***P < 0.001 in (C), (D), (F), and (H). *P < 0.05, **P < 0.01, and ***P < 0.001 for DMM TGF-NP
core/shell structures formed by amphiversus DMM PBS in (I).
philic block copolymers (39–41). Compared to other drug nanocarriers (42),
cartilage degeneration in a rat OA surgery model (35). Delayed the polymeric NPs provide several advantages, including their relaadministration of teriparatide (Forteo), the recombinant human tively small size and the use of similar formulations in different preparathyroid hormone (1-34), was shown to have a chondro-regenerative clinical and clinical studies. In this work, polymeric micellar NPs
effect, which correlated with increased Prg4 mRNA in mouse OA were prepared from biocompatible and biodegradable polymers
articular chondrocytes (36). In our previous study, we demonstrated including PEG-PCL, PLL-PCL, and pegylated phospholipids. PEG,
that EGFR deficiency leads to reduced PRG4 amount in the articu- PCL, PLL, and phospholipids are clinically tested materials with
lar cartilage and that TGF promotes Prg4 expression in bovine well-characterized safety profiles. Moreover, the manufacture of
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knee joints. In our hands, HBEGF OverCol2 and OverAgcER mice do
not show any joint deformity and bone abnormalities. Therefore,
we propose that the therapeutic effect of EGFR signaling depends
on its activity and specificity. Mig6 global knockout and HBEGF
OverDermo1 mice have the highest EGFR activity not only in cartilage
but also in other organs, thus tipping the balance more toward catabolic actions on cartilage. Mig6 CKO mice have increased EGFR
activity but not as high as the previous two models such that they
exhibit anabolic actions first and then catabolic actions. In addition,
we cannot rule out the possibility that Mig6 knockout mice have
off-target effects because Mig6 also regulates signaling pathways
other than EGFR, such as HGF/Met (50). Because of their cartilage
and EGFR specificity, HBEGF OverCol2 and OverAgcER mouse models, as well as joint delivery of TGF-NPs, demonstrate that it is
feasible to precisely control EGFR signaling for cartilage anabolic
actions selectively without incurring undesired catabolic effects.
These observations also suggest that future study of TGF-NPs
should optimize dosage, duration, and ligand specificity to achieve
the best therapeutic effects.
Initial findings revealed that TGF (30) and HBEGF (44) are elevated in degenerated OA cartilage. Accordingly, it was proposed
that EGFR inhibitors could be repurposed for OA treatment. To
date, the results of EGFR inhibitors on rodent OA progression are
mixed and often contradictory, depending on the gender and type
of inhibitors used in experiments (29). In our hands, we constantly
observed accelerated OA by gefitinib treatment (25). Our previous
study clearly showed that EGFR activity is most concentrated in the
superficial layer of articular cartilage, which is drastically reduced
during OA initiation (8). In this study, overactivation of EGFR in
animal models, particularly using inducible Aggrecan-CreER or by
TGF-NP injections, demonstrated that elevating EGFR activation
at the early stage of OA was beneficial. We also provided evidence
that TGF-NP treatment starting from 1 month after DMM surgery remained effective. The underlying mechanisms, as shown
here and in our previous studies, involve the protection of superficial layer from OA-induced destruction. At a later stage when the
superficial zone is disrupted and TGF and HBEGF are elevated,
whether further increasing EGFR activity could still render a protective or even reparative effect on cartilage needs further investigation. During OA degeneration, new chondrocyte cell clusters are
frequently formed under the damaged cartilage surface in an
attempt to repair and regenerate (51). Those cell clusters are proliferative with stem cell properties. However, under normal circumstances, impaired cartilage does not repair by itself. We speculate
that as growth factors for mesenchymal progenitors, TGF and
HBEGF are likely to be up-regulated for forming cell clusters after
damage, yet their endogenous expression is not sufficiently high to
regenerate the cartilage. Therefore, exogenous EGFR ligand might
be helpful in attenuating OA progression even at a late stage.
One additional concern of our treatment approach is the possible carcinogenic effect of activating EGFR signaling. High EGFR
activities due to missense mutations, deletions, and insertions are
often observed in breast, lung, liver, brain tumors, etc. (52). In our
study, we attempted to minimize this possibility by locally overactivating EGFR in cartilage. No obvious changes were observed in vital
internal organs in mice overexpressing HBEGF specifically in cartilage up to 12 months of age or in mice intra-articularly injected with
TGF-NPs. However, long-term pharmacological assays should be
performed before translating our findings into the clinic.
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these NPs is simple, reproducible, and scalable, which could allow
fast translation into clinic use. We further used proximity-based
sortase ligation to enable the highly efficient, site-specific bioconjugation of TGF onto our NPs. Currently, one of the greatest challenges in combining protein-based targeting ligands with NPs is the
low efficiency of bioconjugation. To address this limitation, we used
a new strategy that uses a unique sortase fusion protein for the efficient and site-specific modification of the C terminus of recombinant proteins. On the basis of this method, a DBCO moiety was
ligated to the C terminus of TGF. The availability of the DBCO
group, subsequently, allows for the facile bioconjugation of the
TGF to azide-labeled NPs using highly efficient click chemistry.
Last, the TGF-NPs exhibit therapeutic efficacy, with no detectable
side effects on joint structure and peripheral organs. The TGF-NPs
resolve the issues of short in vivo half-life and low cartilage penetration efficiency of free growth factors. Local delivery of TGF-NPs
into knee joints after OA injury effectively attenuated cartilage
degeneration and blocked SBP sclerosis and joint pain in mice, thus
paving the way toward future translational studies that target EGFR
signaling. We are aware that mouse articular cartilage is much thinner than the human counterpart. Although our culture experiment
suggests that TGF-NP can penetrate at least 1 mm into bovine cartilage, future studies are needed to optimize the nanoformulation to
achieve better penetration in large-animal models before translating this approach into clinical applications.
Activation of EGFR signaling for OA treatment has several concerns. It is well established that EGFR ligands, including TGF and
HBEGF, reduce anabolic gene expression (Sox9, Col2a1, and Aggrecan)
and increase catabolic gene expression (Mmp13) in cultured chondrocytes (30, 43). Our studies using chondroprogenitors derived
from HBEGF OverCol2 articular cartilage showed decreased anabolic
gene expression and Alcian blue staining when they underwent
chondrogenic differentiation in vitro. However, these changes are
relatively modest, and a considerable amount of cartilage matrix still
remained in the pellet. Moreover, histology of adult HBEGF OverCol2
knees revealed no change in type II and type X collagen and proteoglycan amounts, indicating that cell culture data might not be directly correlated to animal data. We also observed that MMP13
expression was decreased in HBEGF OverCol2 chondrogenic culture
but unchanged in the HBEGF OverCol2 joints. These data are contradictory to a previous report that adding HBEGF to chondrocyte
culture increases Mmp13 expression (44). We reason that HBEGF
dosage and in vivo versus in vitro conditions might determine the
final outcomes.
Several EGFR activation mouse models have been investigated
for OA study. Most of them used Mig6 knockout models, all having
elevated EGFR activity in the cartilage. The global ablation of Mig6
causes severe joint deformity in young mice (45), whereas the cartilage-
specific (Col2-Cre) and skeletal-specific (Prx1-Cre) knockout of
Mig6 have much more minor joint phenotypes, with initial anabolic
expansion of articular cartilage followed by modest degeneration or
osteophyte formation at a later age (12, 13). Similar to our study, a
previous report took advantage of DTR to construct Dermo1-Cre HBEGF
(HBEGF OverDermo1) mice (46). At a young age, these mice develop
chondrodysplasia, chondroma, OA-like joint defects, and bone pheno
types. While Dermo1-Cre broadly targets mesenchymal lineage
cells (47), the Col2-Cre (48) and Aggrecan-CreER (49) are more specific
for cartilage tissue. Li et al. (46) also reported that Col2-Cre HBEGF
mice have normal body weight and body size but slightly distorted
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Thermo Fisher Scientific) for 4 days. Knee joints were harvested on
the fifth day or 3 weeks later.
For the TGF-NP treatment study, male C57Bl/6 mice (the Jackson
laboratory) were randomly divided into five groups: sham surgery
(sham), DMM and PBS treatment, DMM and free TGF–DBCO
treatment (TGF-DBCO), DMM and Ctrl-NP treatment (Ctrl-NP),
and DMM and TGF-NP treatment (TGF-NP). Treatments were
given by intra-articular injection of 10 l of PBS, TGF-DBCO
(10 M TGF content), Ctrl-NPs (NP with no TGF conjugation),
or TGF-NPs (10 M TGF content) once every 3 weeks initiated
immediately after DMM surgery. Mice were euthanized 2 months
after surgery (receiving a total number of three injections) or 3 months
after surgery (receiving four injections).

MATERIALS AND METHODS

TGF-NP synthesis
TGF-NPs were prepared via click reaction (27). Briefly, stock
solutions of poly(ethylene glycol) (4000)–polycaprolactone (3000)
copolymer (denoted as PEG-PCL; Polymer Source), polylysine
(3300)–polycaprolactone (4000) copolymer (denoted PLL-PCL), and
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[azido(polyethylene
glycol)-5000] (ammonium salt) (denoted as DSPE-PEG5K-N3;
Avanti Polar Lipids Inc) in chloroform (Sigma-Aldrich) were mixed in
the following molar ratios: PEG-PCL/PLL-PCL/DSPE-PEG5K-N3
(55/20/25). The total amount of PEG-PCL for each of the NP compositions was 1 mg. The chloroform was removed using a direct
stream of nitrogen before vacuum desiccation for overnight. NPs
were formed by adding an aqueous solution (0.1 M PBS, pH 7.4) to
the dried film and incubating in a 60°C water bath for 3 min and
then sonicating for another 3 min at the same temperature. To prepare TGF-NPs, azide-modified NPs were mixed with TGF-DBCO
at a molar ratio of 1 to 1 in 0.1 M PBS (pH 7.4). Reactions were
mixed overnight at room temperature and then purified by centrifugal filter devices (Amicon Ultra-4, 50K MWCO, Millipore Corp.).
Samples were stored in the dark at 4°C.

Study design
This study was performed to evaluate whether activating EGFR signaling specifically in joint cartilage could protect articular cartilage
from OA degeneration. This objective was addressed by (i) examining articular cartilage phenotype in HBEGF OverCol2 and HBEGF
OverAgcER mice, (ii) delineating the cellular and molecular changes
in their articular cartilage, (iii) characterizing their responses toward OA surgery, (iv) synthesizing and characterizing TGF-NPs,
and (v) studying the effect of intra-articular injection of TGF-NPs
on attenuating OA progression. Sample size was determined by the
investigators according to previous experimental experience. The
exact n numbers used in each experiment are indicated in the respective figure legends. For in vivo experiments, data from animals
that died or had severe health problems during the experiments
were excluded. Samples were assigned randomly to the experimental and control groups. Animal or sample allocation and data acquisition in vivo or ex vivo were performed in a blinded manner. The
investigators were not blinded during data analysis.
Animals
All animal work performed in this study was approved by the Institutional Animal Care and Use Committee at the University of
Pennsylvania. In accordance with the standards for animal housing,
mice were group housed at 23° to 25°C with a 12-hour light/dark cycle
and allowed free access to water and standard laboratory pellets.
Col2-Cre mice or Aggrecan-CreER mice were bred with Rosa-DTR
mice to generate Col2-Cre DTR (HBEGF OverCol2) and Aggrecan-CreER
DTR (HBEGF OverAgcER) mice, respectively, and their WT (DTR- or
Cre-only) siblings. All mouse lines were purchased from the Jackson
laboratory.
To induce OA, male mice 3 months of age were subjected to
DMM surgery or sham surgery at right knees as described previously
(25). Briefly, in DMM surgery, the joint capsule was opened immediately after anesthesia, and the medial meniscotibial ligament was
cut to destabilize the meniscus without damaging other tissues. In
sham surgery, the joint capsule was opened in the same fashion but
without any further damage.
HBEGF OverAgcER mice and WT controls received tamoxifen (Sigma-
Aldrich) injections (75 mg/kg per day) for 5 days before DMM surgery at 3 months of age. For the EGFR inhibitor treatment study,
these mice additionally received vehicle (0.5% methyl cellulose)
or gefitinib (100 mg/kg; LC Laboratories) via oral gavage once every
other day for 8 weeks after surgery. For EdU incorporation study,
3-day-old mice received intraperitoneal injections of EdU (2.5 mg/kg;
Wei et al., Sci. Transl. Med. 13, eabb3946 (2021)
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Cartilage explant, cell culture, immunoblotting, and
real-time reverse transcription PCR analysis
Chondroprogenitors were harvested from articular cartilage of
5-month-old mouse knee joints. Briefly, cartilage was peeled from
femoral condyles and tibial plateau by sterile scalpel under dissection microscope and incubated in 0.25% trypsin (Invitrogen) for
1 hour, followed by 2 hours of digestion with type I collagenase
(900 U/ml; Worthington Biochemical). Dissociated cells from the
second digestion were cultured in Gibco Dulbecco’s modified Eagle’s
medium (DMEM) medium containing 10% fetal bovine serum
(FBS), streptomycin (100 g/ml), and penicillin (100 U/ml). For
CFU-F assay, 1 × 104 cells were seeded in a six-well plate and cultured for 7 days followed by crystal violet staining. CFU number
was counted under microscope. For proliferation assay, cells were
seeded in culture medium. Cell counting was performed on the indicated days. For apoptosis assay, cells at 40 to 60% confluency were
serum starved overnight and then pretreated with either vehicle or
TNF (25 ng/ml; Pepro-Tech). Two days later, apoptotic cells were
quantified using ethidium bromide (5 mg/ml; Sigma-Aldrich) and
acridine orange (5 mg/ml; Thermo Fisher Scientific) staining as
described previously (53). For chondrogenic differentiation assay,
confluent cells were cultured in differentiation medium [DMEM, streptomycin (100 g/ml), penicillin(100 U/ml), 1% insulin-transferrin-
selenous acid (ITS)+ Premix (Corning), l-proline (40 g/ml), 0.1 M
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There is a great unmet medical need for a disease-modifying OA
drug. In this study, we have demonstrated the feasibility of targeting
EGFR signaling to block OA initiation and constructed a drug for
such treatment without obvious side effects. This is just the initial
step toward the translation of our findings into clinical usage. Because most patients with OA are already at middle or late OA stages,
future experiments should test the efficacy of TGF-NPs after OA
has well developed using large-animal models. Optimization of the
structure of conjugates, likely using different EGFR ligands, and the
dosage of conjugates should be explored to achieve favorable treatment outcomes. Such comprehensive studies will shed light on
developing disease-modifying drugs that benefit patients with OA.
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Statistical analysis
Data are expressed as means ± SEM and analyzed by t tests, oneway analysis of variance (ANOVA) with Dunnett’s or Tukey’s
posttest, and two-way ANOVA with Bonferroni’s or Tukey’s posttest
for multiple comparisons using Prism 8 software (GraphPad Software). For cell culture experiments, observations were repeated independently at least three times with a similar conclusion, and only
data from a representative experiment are presented. Values of
P < 0.05 were considered significant.
SUPPLEMENTARY MATERIALS

stm.sciencemag.org/cgi/content/full/13/576/eabb3946/DC1
Materials and Methods
Fig. S1. HBEGF OverCol2 mice have normal body weight and body length.
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Fig. S2. HBEGF OverCol2 mice overexpress HBEGF in cartilage.
Fig. S3. HBEGF OverCol2 mice have normal joint structure.
Fig. S4. Overexpressing HBEGF in articular cartilage does not affect long bone structure.
Fig. S5. Mesenchymal progenitors in synovium are not affected by HBEGF overexpression in
cartilage.
Fig. S6. Overexpressing HBEGF in cartilage does not affect cartilage matrix composition and
cartilage degradation.
Fig. S7. Overexpressing HBEGF in cartilage does not affect vital internal organs.
Fig. S8. HBEGF OverAgcER mice have increased HBEGF expression and EGFR activity in knee
articular cartilage.
Fig. S9. Synthesis and characterization of PLL-PCL.
Fig. S10. TGF-NPs result in similar morphology changes in chondrocytes as free TGF.
Fig. S11. TGF-NPs are functional on human articular cartilage.
Fig. S12. TGF-NPs doped with PLL-PCL enhance bovine cartilage uptake.
Fig. S13. TGF-NPs doped with PLL-PCL improve their penetration and retention in bovine
cartilage tissue.
Fig. S14. Biodistribution of TGF-NPs within the knee joints and some major organs.
Fig. S15. TGF-NP treatment attenuates OA progression after DMM surgery in mice.
Fig. S16. TGF-NP treatment starting at 1 month after DMM attenuates further OA progression.
Fig. S17. The mechanism underlying the protective action of EGFR overactivation on articular
cartilage after DMM surgery.
Fig. S18. Intra-articular injections of TGF-NPs for 2 months do not affect vital internal organs
and gross joint morphology.
Table S1. Mouse real-time PCR primer sequences.
Data file S1. Individual subject-level data (Excel file).
Data file S2. Western blotting films (PDF).
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(50 g/ml), and TGF3 (10 ng/ml)]. Media were changed twice a week.
Synovial mesenchymal progenitors were harvested from 5-month-
old mouse knee joints as described previously with minor modifications (54). Briefly, the quadricep reversing approach was used to
harvest mouse synovium, which was then incubated in 0.25% trypsin
for 0.5 hours, followed by 1-hour digestion with type I collagenase
(300 U/ml). Dissociated cells from the second digestion were cultured in DMEM medium containing 10% FBS, streptomycin (100 g/ml),
and penicillin (100 U/ml). For CFU-F assay, 4 × 103 cells were seeded
in a six-well plate and cultured for 10 days followed by crystal violet
staining. CFU-F number was counted under microscope.
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Explants were harvested from femoral condyle area with normal
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change on day 3, cartilage explants were washed three times with PBS
and processed either for RNA extraction or for paraffin sectioning.
To perform Western blot, cell lysate was solubilized in radioimmunoprecipitation assay buffer [50 mM tris (pH 7.4), 100 mM
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with protease inhibitor (Sigma-Aldrich). Cell lysate (50 mg) was
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-Actin (1:3000; CST, 4970), and secondary antibodies (Vector Laboratories), followed by chemiluminescence (Amersham ECL Western
Blotting Detection Reagents, GE Healthcare).
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(Sigma-Aldrich). TaqMan Reverse Transcription kit (Applied Biosystems) was used to reverse transcribe mRNA into complementary
DNA. After this, polymerase chain reaction (PCR) was performed
using a Power SYBR Green PCR Master Mix kit (Applied Biosystems).
The primer sequences for the genes used in this study are listed in
table S1.
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Enhancing EGFR to offset osteoarthritis
Cartilage degeneration in osteoarthritis causes pain and limits mobility. Wei et al. investigated epidermal
growth factor receptor (EGFR) signaling as a potential targeted disease-modifying treatment, because EGFR
activity is linked to cartilage homeostasis. Cartilage-specific genetic overactivation of EGFR resulted in enlarged
cartilage, an expanded tissue progenitor cell population, and resistance to surgically induced osteoarthritis in mice.
Treating mice with transforming growth factor −α (an EGFR ligand) conjugated to nanoparticles via intra-articular
injections protected against cartilage degeneration and attenuated pain in an osteoarthritis model. Results show
how targeting EGFR signaling could potentially treat osteoarthritis.

